Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Diagnostics
Phase I clinical trial initiated for EP-2104R
September 9th, 2004
EPIX Medical, Inc., (EPIX), a developer of pharmaceuticals for magnetic resonance imaging (MRI), has initiated its first human clinical trial of EP-2104R, an injectable MRI contrast agent which specifically targets blood clots, or thrombi, in the body. EP-2104R binds selectively to fibrin, an important component of thrombus, and is designed to provide a bright MR image to allow the detection of small clots in arteries and veins, many of which may be undetectable with currently available imaging methods. Early thrombus detection may enable better therapeutic decision-making for patients with cardiovascular disease. The trial will be conducted in the U.S. under a U.S....
Source: Blood Weekly (2004-09-09)
|
